Lyell Immunopharma, Inc. (LYEL)
NASDAQ:LYEL
Want to see LYEL full AI Analyst Report?
Top Page
Lyell Immunopharma
(NASDAQ:LYEL)
Select Model
Select Model
Rating:43Neutral
Price Target:
$12.00
▼(-50.02% Downside)
Action:Reiterated
Date:06/17/26
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, and sustained negative free cash flow) and a bearish technical setup (price below major moving averages with negative MACD). A low-leverage balance sheet and a positive governance vote provide some support, but they are not enough to offset ongoing cash burn and downtrending price action.
Positive Factors
Platform focus on T‑cell dysfunction
Lyell’s platform explicitly targets T‑cell dysfunction and exhaustion and develops engineered cellular therapies for solid tumors. A platform addressing a core biological failure mode supports multiple program opportunities, persistent IP value and durable differentiation versus single‑asset peers.
Negative Factors
Large and persistent cash burn
Sustained annual cash outflows in the low hundreds of millions create ongoing financing needs and elevate dilution risk. Large burn limits internal runway, forces reliance on external capital or collaborations, and constrains the company’s ability to advance multiple clinical programs simultaneously.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform focus on T‑cell dysfunction
Lyell’s platform explicitly targets T‑cell dysfunction and exhaustion and develops engineered cellular therapies for solid tumors. A platform addressing a core biological failure mode supports multiple program opportunities, persistent IP value and durable differentiation versus single‑asset peers.
Read all positive factors
Lyell Immunopharma (LYEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$316.18M
Dividend YieldN/A
Average Volume (3M)74.95K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue Growth-52.31%
EPS Growth49.06%
CountryUS
Employees300
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.98
Shares Outstanding23,334,087
10 Day Avg. Volume75,611
30 Day Avg. Volume74,954
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue8.01K
Enterprise Value/Gross Profit-107.93
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$37.50Price Target Upside56.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.53
Revenue Forecast (FY)$11.71K
Lyell Immunopharma Business Overview & Revenue Model
Company Description
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an e...
How the Company Makes Money
As a clinical-stage biotechnology company, Lyell Immunopharma has not historically generated meaningful recurring revenue from product sales because it does not have approved commercial therapies. Its cash inflows have primarily consisted of (1) c...
Lyell Immunopharma Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.00K | 36.00K | 61.00K | 130.00K | 84.68M | 10.65M |
| Gross Profit | -2.30M | -11.50M | 61.00K | 130.00K | 84.68M | 10.65M |
| EBITDA | -238.99M | -262.91M | -200.64M | -214.38M | -165.10M | -236.59M |
| Net Income | -246.41M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M |
Balance Sheet | ||||||
| Total Assets | 350.63M | 340.05M | 490.86M | 750.03M | 937.56M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 254.02M | 247.22M | 370.53M | 546.22M | 640.15M | 614.79M |
| Total Debt | 48.85M | 50.99M | 58.97M | 63.17M | 67.70M | 67.82M |
| Total Liabilities | 76.96M | 91.85M | 108.03M | 95.08M | 104.31M | 197.62M |
| Stockholders Equity | 273.67M | 248.20M | 382.82M | 654.95M | 833.25M | 929.79M |
Cash Flow | ||||||
| Free Cash Flow | -134.42M | -150.80M | -162.86M | -166.38M | -193.83M | -191.75M |
| Operating Cash Flow | -133.80M | -150.02M | -162.39M | -163.69M | -169.56M | -126.25M |
| Investing Cash Flow | 2.01M | 54.10M | 122.42M | 184.05M | -11.54M | -121.57M |
| Financing Cash Flow | 102.13M | 50.41M | 1.33M | 1.74M | 10.63M | 401.24M |
Lyell Immunopharma Technical Analysis
Negative
24.01
Price Trends
18.89
Negative
20.86
Negative
20.75
Negative
Market Momentum
-1.72
Negative
31.44
Neutral
40.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Negative. The current price of 24.01 is above the 20-day moving average (MA) of 14.82, above the 50-day MA of 18.89, and above the 200-day MA of 20.75, indicating a bearish trend. The MACD of -1.72 indicates Negative momentum. The RSI at 31.44 is Neutral, neither overbought nor oversold. The STOCH value of 40.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYEL.
Lyell Immunopharma Risk Analysis
Lyell Immunopharma disclosed 66 risk factors in its most recent earnings report. Lyell Immunopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lyell Immunopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $312.29M | -1.50 | -70.79% | ― | ― | 28.56% | |
46 Neutral | $47.25M | -1.31 | -81.25% | ― | ― | 28.17% | |
44 Neutral | $377.52M | -2.12 | -677.38% | ― | 7.97% | 59.82% | |
43 Neutral | $316.18M | -1.10 | -85.71% | ― | -52.31% | 49.06% | |
43 Neutral | $739.85M | -2.57 | -102.69% | ― | ― | -13.96% |
* Healthcare Sector Average
LYEL
Lyell Immunopharma
12.44
2.74
28.25%
RCKT
Rocket Pharmaceuticals
2.80
0.08
2.94%
EDIT
Editas Medicine
2.36
0.22
10.28%
MREO
Mereo Biopharma Group Plc
0.29
-2.51
-89.57%
REPL
Replimune Group
8.78
-0.73
-7.63%
Lyell Immunopharma Corporate Events
Executive/Board ChangesShareholder Meetings
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting
Positive
Jun 15, 2026
On June 10, 2026, Lyell Immunopharma, Inc. held its 2026 annual meeting of stockholders virtually, with a quorum of 67.31% of outstanding shares represented, and stockholders voting on director elections, auditor ratification and executive compens...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.